BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nucresiran readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nucresiran\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07223203-10761@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20271227
DTEND;VALUE=DATE:20271228
SUMMARY:Nucresiran: Phase 3 readout est. (NCT07223203)
DESCRIPTION:Nucresiran\, phase 3\, Transthyretin Amyloidosis with Polyneuro
 pathy.\nStudy: TRITON-PN: A Study to Evaluate the Efficacy and Safety of N
 ucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyn
 europathy\nEstimated primary completion: 27 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nucresiran#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07223203
URL:https://assetmemo.bio/drug/nucresiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052903-10761@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Nucresiran: Phase 3 readout est. (NCT07052903)
DESCRIPTION:Nucresiran\, phase 3\, Transthyretin Amyloidosis with Cardiomyo
 pathy.\nStudy: TRITON-CM: A Study to Evaluate Nucresiran in Patients With 
 Transthyretin Amyloidosis With Cardiomyopathy\nEstimated primary completio
 n: 28 May 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nucre
 siran#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07052903
URL:https://assetmemo.bio/drug/nucresiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
